louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03090048: Vitamin A and Azithromycin for Acne Vulgaris
Official title: Treatment of Acne for Cases Resistant to Currently Available Measures Via Vitamin A With or Without Azithromycin in Topical Formulations
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: EARLY_PHASE1
Conditions: Acne Vulgaris
Lead sponsor: Manchanda Medical Clinic
Sponsor class: OTHER
First posted: 2017-03-24
Enrollment: 30
Sex: ALL
Minimum age (years): 12
Maximum age (years): 45
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients seen with acne lesions not having responded to existing treatments will be offered a placebo or a topical preparation consisting of Vitamin A USP with or without Azithromycin for a duration of 4-6 months USP for the objective of resolving the lesions without systemic side effects and via weekly follow-ups.

Detailed description: The concentrations of the active ingredients is based on the enclosed articles and the formulations have been modified with an objective of minimizing the side effects.

Eligibility criteria: Inclusion Criteria:

* Patients with active lesions

Exclusion Criteria:

* Patients on a treatment
* Asymptomatic patients

Primary outcomes:
measure: Measurement (dimensions) of acne lesions
timeFrame: Every 4 weeks up to16 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Surrey
country: Canada
facility: Manchanda Mc
state: British Columbia
Study officials:
affiliation: M.D.
name: Vinod C Tawar
role: STUDY_DIRECTOR
References:
citation: Bartlett KB, Davis SA, Feldman SR. Tolerability of topical antimicrobials in treatment of acne vulgaris. J Drugs Dermatol. 2014 Jun;13(6):658-62.
Clinical trial NCT02706730: A 6-Month Extension Study of OTO-104 in Meniere's Disease
Official title: A 6-Month, Multicenter, Phase 3, Open-Label Extension Safety Study of OTO-104 Given At 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's Disease
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Meniere's Disease
Lead sponsor: Otonomy, Inc.
Sponsor class: INDUSTRY
First posted: 2016-03-11
Enrollment: 189
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is an open-label extension study of a single intratympanic injection of OTO-104 given every 3 months for a total of 2 injections. Subjects must have completed either Otonomy study 104-201102 (Phase 2b study of OTO-104) or 104-201506 (Phase 3 study of OTO-104) in order to be eligible for this open-label extension study.


Eligibility criteria: Inclusion Criteria includes, but is not limited to:

* Subject has completed the OTO-104 Phase 2b (104-201102) or Phase 3 (104-201506) clinical study.
* Subject has a diagnosis of definite unilateral Meniere's disease by 1995 AAO-HNS criteria

Exclusion Criteria includes, but is not limited to:

* Subject is pregnant or lactating.
* Subject has a history of immunodeficiency disease.
* Subject has experienced an adverse reaction to intratympanic injection of steroids.

Primary outcomes:
measure: Otoscopic Examination - Tympanic Membrane Perforation at Week 24 (Month 6)
timeFrame: 6 Months
Secondary outcomes:
Other outcomes:
Locations:
city: San Diego
country: United States
facility: Many sites in US. Refer to the contact info listed below.
state: California
Study officials:
affiliation: Otonomy, Inc.
name: Kathie Bishop, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT05461430: Mass Response of Tumor Cells As a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Official title: Mass Response of Tumor Cells As a Biomarker for Rapid Therapy Guidance
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Pleural Effusion, Malignant
Ascites, Malignant
Carcinoma
Carcinoma, Hepatocellular
Carcinoma, Renal Cell
Carcinoma, Renal
Carcinoma, Small Cell
Carcinoma, Non-Small-Cell Lung
Carcinoma, Pancreatic Ductal
Carcinoma, Neuroendocrine
Carcinoma, Thymic
Carcinoma, Pancreatic
Carcinoma Breast
Carcinoma, Ovarian
Carcinoma Bladder
Carcinoma of Unknown Primary
Carcinoma of the Head and Neck
Carcinoma of the Oropharynx
Carcinoma of the Larynx
Carcinoma of the Bladder
Carcinoma of Esophagus
Carcinoma of the Nasopharynx
Carcinoma of the Penis
Carcinoma of the Cervix
Carcinoma of the Anus
Carcinoma of the Vulva
Carcinoma of the Appendix
Carcinoma of the Oral Cavity
Cholangiocarcinoma
Melanoma
Mesothelioma
Pancreatic Cancer
Keywords: Breast Cancer
Lung Cancer
NSCLC
Occult Cancer
Ovarian Cancer
Melanoma
Mesothelioma
Gastrointestinal Stromal Tumor
Gastric Cancer
Colon Cancer
Cervical Cancer
Lead sponsor: Travera Inc
Sponsor class: INDUSTRY
Collaborators: name: xCures
First posted: 2022-07-18
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: This pilot study will utilize samples from as many as 200 patients with a known carcinoma undergoing routine draining of malignant fluids or sampling of their tumor tissue for diagnostic or palliative standards of care (SOC).

Brief summary: The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.


Eligibility criteria: Inclusion Criteria:

1. Patient is ≥18 years of age
2. Written Informed Consent provided by patient
3. Diagnosis of any kind of carcinoma
4. Malignant fluid (e.g. pleural effusion or ascites) drainage OR tumor tissue resection OR tumor tissue needle biopsy is clinically indicated as part of SOC
5. Proceeding onto therapy for treatment
6. Informed consent obtained for the XCELSIOR longitudinal outcomes registry (NCT03793088)

Exclusion Criteria:

1. Lack of informed consent
2. Unable to obtain sufficient sample

Primary outcomes:
measure: BOR
timeFrame: 12 months
Secondary outcomes:
measure: PFS
timeFrame: 24 months
Other outcomes:
Locations:
city: Oakland
country: United States
facility: xCures
state: California
Study officials:
affiliation: Travera Inc
name: Mark Stevens, Phd
role: PRINCIPAL_INVESTIGATOR
affiliation: Travera Inc
name: Rob Kimmerling, Phd
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02057848: Carbohydrates to Prevent Hypoglycaemia During Physical Activity in Patients With Type 1 Diabetes
Official title: A Prospective, Randomized Trial Testing Different Regimens of Carbohydrate Administration to Prevent Hypoglycaemia During a Standardized Bout of Moderate Physical Activity in Patients With Type 1 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypoglycaemia
Keywords: carbohydrate, hypoglycemia
Lead sponsor: Diabeteszentrum Bad Lauterberg im Harz
Sponsor class: OTHER
First posted: 2014-02-07
Enrollment: 37
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: Backgrounds/Aims: It was the aim to prospectively study the optimum regime of "preventive" carbohydrate administration for prevention of hypoglycaemic episodes during a standardized bout of physical activity.

Detailed description: Research design and methods: 24 patients with type 1 diabetes participated in one experiment without physical activity and in three experiments with a 4 km, 60 min hike starting at 2 p.m., either administering 2 x 10 g or 2 x 20 g carbohydrates (muesli bars) before starting and at 30 min (during the hike). Plasma glucose was determined with a laboratory method and additional carbohydrates needed to treat hypoglycaemia between 2 and 8 p.m. were recorded.

Eligibility criteria: Inclusion Criteria:

Type 1 diabetes mellitus, 18-75 years, BMI 18-35 kg/m², Diabetes duration \> 1 year

Exclusion Criteria:

General bad health status, Malignant diseases, Systemic glucocorticoid treatment, Coronary heart disease, Uncontrolled arterial hypertension, Acute infection diseases, Diseases of liver or kidney with significant organ malfunction, Abuse of alcohol or other drugs, Participation in another trial in the last 3 months

-

Primary outcomes:
measure: Plasma glucose
timeFrame: 6 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Bad Lauterberg
country: Germany
facility: Diabeteszentrum
Study officials:
affiliation: Diabeteszentrum
name: Michael A. Nauck, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01814930: Adolescent Postpartum Contraceptive Counseling Intervention
Official title: Evaluation of a Brief Standardized Postpartum Counseling Intervention's Effect on Repeat Pregnancy Rates Contraceptive Choice/Use/Continuation/Satisfaction in Adolescents
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Adolescent Pregnancy
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
First posted: 2013-03-20
Enrollment: 100
Sex: FEMALE
Minimum age (years): 14
Maximum age (years): 19
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: Postpartum contraceptive counseling varies widely in its provision; no standardized practice has been well-established by the literature. We intend to evaluate how directed postpartum contraceptive counseling to adolescents aged 14-19 affects key outcomes over time. Subjects will be randomized to receive either the standardized contraceptive counseling intervention or routine postpartum care. We will then assess the difference in repeat pregnancy rates between the two groups


Eligibility criteria: Inclusion Criteria:

* 14-19 years old
* primiparous
* immediately postpartum
* delivery of a full term live singleton infant (\>37 weeks) at HUP

Exclusion Criteria:

* not planning to reside in/near Philadelphia for the next year

Primary outcomes:
measure: The primary outcome is repeat pregnancy rate
timeFrame: 1 year
Secondary outcomes:
measure: Contraceptive choice, use and continuation rates postpartum as well as contraceptive satisfaction rates
timeFrame: 1 year
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: University of Pennsylvania
name: Courtney A Schreiber, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Frarey A, Gurney EP, Sober S, Whittaker PG, Schreiber CA. Postpartum contraceptive counseling for first-time adolescent mothers: a randomized controlled trial. Arch Gynecol Obstet. 2019 Feb;299(2):361-369. doi: 10.1007/s00404-018-4969-0. Epub 2018 Nov 23.
Clinical trial NCT03599830: Study of the Cognition of Patients Treated With Immunotherapy
Official title: Study of the Cognition of Patients Treated With
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Patients With Cancer Who Start Immunotherapy
All Neoplasms
Keywords: Immunotherapy
Cognition
Cancer
Lead sponsor: Centre Francois Baclesse
Sponsor class: OTHER
First posted: 2018-07-26
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The investigator's longitudinal pilot study aims to evaluate for the first time the impact of immunotherapy on cognition in oncology.

Due to the recent nature of immunotherapy, its side effects and impact on quality of life are still poorly understood and, to date, there is no published study evaluating the impact of immunotherapy on cognition in patients treated for cancer.

The study consists of the passation of 3 neuropsychological assessments over a period of 6 months in cancer patients who start immunotherapy


Eligibility criteria: Inclusion Criteria:

* Patient over the age of 18,
* Patient with cancer and having to initiate treatment with immunotherapy alone
* Treatment with immunotherapy will include either an anti-PD1 / L1 or Anti CTLA4 monotherapy or combination,
* Patients may have received other antitumor treatments other than immunotherapy but these should be stopped at the time of initiation of immunotherapy
* Performance Status \<2
* Patient at the level of studies 3 "end of primary studies" minimum (Barbizet scale),
* Mastery of the French language.
* Patient affiliated to a social security system
* Patient having attested in writing of his non-opposition to participate in the study

Exclusion Criteria:

* Previous treatment with immunotherapy
* Another anti-tumor treatment underway
* Primary cancer of the central nervous system or cerebral metastasis, symptomatics and not controlled
* Abuse of alcohol or drug use
* Severe visual and / or auditory deficiency,
* Refusal of participation of the patient.
* Patient deprived of liberty or under guardianship
* Patient unable to follow the study for geographical, social or psychopathological reasons

Primary outcomes:
measure: Change in cognitive function (at least in a cognitive domain)
timeFrame: between inclusion and 3 months.
Secondary outcomes:
Other outcomes:
Locations:
city: Amiens
country: France
facility: Chu Amiens
city: Caen
country: France
facility: CHU CAEN
city: Caen
country: France
facility: Centre François Baclesse
city: Lille
country: France
facility: Chru Lille
Study officials:
References:
Clinical trial NCT03753230: Clinical Qualification Study of Electroencephalographic Mobile Equipment for the Capture of Emotions
Official title: Clinical Qualification Study of Electroencephalographic Mobile Equipment for the Capture of Emotions
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Musical Emotions
Lead sponsor: Centre Hospitalier Universitaire de Besancon
Sponsor class: OTHER
First posted: 2018-11-26
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The study aim to determine the reliability of various EEG wireless headsets. Their signal will be compared to standard high-density EEG recording during music listening.


Eligibility criteria: Inclusion Criteria:

* Right handed healthy people
* sensitive to "music chill" (Barcelona Reward music Questionnaire\>50)
* having given their participation agreement
* individual with health insurance coverage.

Exclusion Criteria:

* Pregnant women
* individuals in "exclusion period" of another study
* subjects with auditory deficits

Primary outcomes:
measure: Quality and spatial/temporal coherence in oscillatory responses patterns recorded with EEG wireless headsets (Emotiv and g.tec) and with the EEG high density gold standard
timeFrame: Up to 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05180630: Sound Quality Comparisons With Different Hearing Aid Couplings and Venting Systems
Official title: Sound Quality and Occlusion Comparisons With Different Hearing Aid Couplings and Venting Systems
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hearing Loss, Sensorineural
Lead sponsor: Sonova AG
Sponsor class: INDUSTRY
First posted: 2022-01-06
Enrollment: 17
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: Participants will be comparing the sound quality of their own voice and the sound quality of streamed music using universal couplings and a custom earmold with a dynamic vent.


Eligibility criteria: Inclusion Criteria:

* Mild to severe bilateral sensorineural hearing loss
* hearing must be symmetrical below 500 Hz
* must live within 30 miles of Aurora IL

Exclusion Criteria:

-

Primary outcomes:
measure: Sound Quality of Streamed Music Rating Scale
timeFrame: 1 day
measure: Own Voice Sound Quality Rating Scale
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Aurora
country: United States
facility: Sonova US
state: Illinois
Study officials:
References:
Clinical trial NCT03796130: Does Myomectomy for Intramural Fibroid Improve ART Outcome?
Official title: Does Myomectomy for Intramural Fibroid Improve ART Outcome? A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Fibroid Uterus
Lead sponsor: Mansoura University
Sponsor class: OTHER
Collaborators: name: Alexandria University
name: Zagazig University
name: Sohag University
name: Assiut University
First posted: 2019-01-08
Enrollment: 80
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Intamural fibroids (myoma) do exist in some infertile women undergoing IVF treatment. There is controversy whether myomectomy before IVF treatment could improve IVF outcome. This trial will examine whether myomectomy in those patients could improve the results.

Detailed description: This study will include women who have intramural myoma ranging from 3-5 cm

The participants will be randomly allocated into two groups.

In group (1): myomectomy will be performed before ART

In group (2):women will have their trial of ART without myomectomy

In group A, ART will be performed 3 months after myomectomy if the uterine cavity is not opened and 6 months after myomectomy upon inadvertent opening of the uterine cavity during surgery

Eligibility criteria: Inclusion Criteria:

* Inclusion criteria:
* Women with intramural fibroid without any cavity involvement
* Age ˂ 35 years
* I onCSI or IVF cycles
* normal uterine cavity

Exclusion Criteria:

* Exclusion criteria:
* low ovarian reserve (AFC \< 7 and or AMH \< 1.1 ng/ml)
* Endometrioma
* Untreated hydrosalpinx
* Non obstructive azoospermia
* Any other cavitary lesions (Asherman syndrome, Mullerian anomalies)
* recurrent implantation failure

Primary outcomes:
measure: The primary outcome will be ongoing pregnancy rate
timeFrame: 3 months after embryo transfer
Secondary outcomes:
measure: -Implantation rate
timeFrame: 15 days after embryo transfer
measure: -clinical pregnancy rate
timeFrame: 5 weeks after embryo transfer
Other outcomes:
Locations:
city: Mansoura
country: Egypt
facility: Mansoura University Hospital
state: Dakahlia
Study officials:
affiliation: Mansoura University
name: Ahmed Gibreel, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Mansoura University
name: Mohamed S Abdelhafez, MD
role: STUDY_DIRECTOR
affiliation: Sohag University
name: Salah Rasheed, MD
role: STUDY_DIRECTOR
affiliation: Assiut Universit
name: Ahmed Nasr, MD
role: STUDY_DIRECTOR
affiliation: Alexandria University
name: Hisham A Saleh, MD
role: STUDY_DIRECTOR
affiliation: Alexandria University
name: Hassan El Maghraby, MD
role: STUDY_DIRECTOR
affiliation: Zagazig University
name: Eman El Gindy, MD
role: STUDY_CHAIR
affiliation: Zagazig University
name: Hoda Sibai, MD
role: STUDY_DIRECTOR
affiliation: Mansoura University
name: Hamed Yossef, MD
role: STUDY_CHAIR
References:
Clinical trial NCT00592930: Olanzapine in the Treatment of Anorexia Nervosa
Official title: Pilot Study of the Efficacy of Olanzapine in the Treatment of Anorexias Nervosa
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Anorexia Nervosa
Keywords: anorexia nervosa, treatment, adolescents, olanzapine
Lead sponsor: Northwell Health
Sponsor class: OTHER
Collaborators: name: Eli Lilly and Company
First posted: 2008-01-14
Enrollment: 20
Sex: FEMALE
Minimum age (years): 12
Maximum age (years): 23
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study compared 10 weeks of treatment with olanzapine versus placebo in adolescent females with anorexia nervosa-restricting type who were undergoing acute treatment on an inpatient unit or a day hospital program that specializes in the treatment of eating disorders.


Eligibility criteria: Inclusion Criteria:

* Females, ages 12-23

Exclusion Criteria:

* Binge-purge type

Primary outcomes:
measure: weight gain
timeFrame: 10 weeks
Secondary outcomes:
measure: measures of psychiatric symptoms
timeFrame: 10 weeks
Other outcomes:
Locations:
city: New Hyde Park
country: United States
facility: Schneider Children's Hospital
state: New York
Study officials:
affiliation: Schneider Children's Hospital
name: Vivian Kafantaris, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kafantaris V, Leigh E, Hertz S, Berest A, Schebendach J, Sterling WM, Saito E, Sunday S, Higdon C, Golden NH, Malhotra AK. A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol. 2011 Jun;21(3):207-12. doi: 10.1089/cap.2010.0139.
Clinical trial NCT06938230: Coronavirus Disease of 2019 (COVID-19) Health Education Initiative for School Safety
Official title: Promoting A School Culture of Safety in the Era of COVID-19: Assessing Feasibility and Impact of a Health Education Initiative
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: COVID-19
Lead sponsor: University of Miami
Sponsor class: OTHER
Collaborators: name: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
First posted: 2025-04-22
Enrollment: 112
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The purpose of this study is to compare COVID-19 knowledge, experiences, and health behaviors between participants who received the health initiative and those who did not.


Eligibility criteria: Inclusion Criteria:

* Parents/guardians of students enrolled in:
* Arch Creek Elementary, Fulford Elementary
* Greynolds Park Elementary
* Sabal Palm Elementary
* North Miami Middle school,
* John F Kennedy (JFK) Middle School
* North Miami Senior High
* North Miami Beach High
* Booker T. Washington High
* Able to read and write in English, Spanish, or Creole at a 5th grade level

Exclusion criteria:

* Does not speak:
* English
* Spanish
* Creole

Primary outcomes:
measure: Evaluation of acceptability of intervention as measured by Acceptability Questionnaire
timeFrame: up to 6 months
measure: Evaluation of confidence in COVID healthcare decision making as measured by COVID Confidence Questionnaire
timeFrame: up to 6 months
measure: Number of caregivers who received COVID-19 vaccine
timeFrame: up to 6 months
measure: Number of children who received COVID-19 vaccine
timeFrame: up to 6 months
measure: Health behaviors as measured by Health Behavior Questionnaire
timeFrame: up to 6 months
Secondary outcomes:
measure: PTSD as measured by the University of California Los Angeles (UCLA) Brief COVID-19 Screen for Child/Adolescent Post Traumatic Stress Disorder (PTSD)
timeFrame: up to 6 months
measure: COVID anxiety as measured by the Coronavirus Anxiety Scale
timeFrame: up to 6 months
Other outcomes:
Locations:
city: Miami
country: United States
facility: University of Miami
state: Florida
Study officials:
affiliation: University of Miami
name: Lisa Gwynn, DO
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Miami
name: Elizabeth Pulgaron, PhD
role: PRINCIPAL_INVESTIGATOR
References: